Podcasts about Wysocki

Charlie Eisenhood and Josh Mansfield talk about Ricky Wysocki and Kona Montgomery's departures from Dynamic Discs a year early. Then they're joined by new DD signing Evan Smith for a wide-ranging interview in his first appearance on the show.0:00 Wysocki, Kona gone from DD19:00 Evan Smith Interview, Putting & Confidence29:45 His Contract, Ricky's Departure from DD39:25 Goals, Areas for Improvement47:00 Most Exciting Card Mates51:00 Impressions & Marketablity of Evan Smith

UB's Annette Wysocki on a new Gallup finding nurses are most trusted full 258 Thu, 16 Jan 2025 17:49:26 +0000 rS5Q5GgtdREqjUdrT9rgUcLon7Os8cip news & politics,news WBEN Extras news & politics,news UB's Annette Wysocki on a new Gallup finding nurses are most trusted Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False https://player.amperwave

Why women still carry the mental load when it comes to our children's healthcare. In this episode, we break down why women still carry a majority of the mental load when it comes to our kids and their medical records. Because of the way American structures its paid leave for women postpartum, they disproportionately take their children to health care appointments - both well checks and sick visits. Families report mothers are usually the parent who takes time off when children need to stay home sick.Gender roles play a part in why women tend to know more about their kids' medical histories.Despite the overwhelming evidence that when dads participate in their children's health care, children have a more positive life outcome. "There is scientific evidence that shows father involvement in a child's healthcare, it has a positive influence on health outcomes for the child.Wysocki and Gavin (2006) found that for children with chronic health conditions, such as asthma or type 1 diabetes, greater direct paternal involvement in disease management was associated with greater treatment adherence and overall quality of life.Levy-Shiff et al. (1990) reported that more frequent visits by fathers to the hospital to see their preterm infants fostered higher infant weight gain, and were associated with more positive subsequent father-infant interactions and better child social development and adaptation.Not only is there a benefit to the child's health outcomes but studies also show increased father-child bonding."What can we do about this?Encourage dads to download and check their pediatrician's medical appAllow dads to own appointments/conditions from start to finishDecrease maternal gatekeepingStart a shared medical history document/noteMerch Vision Board

Eintrag #31: Liebes Doc's Diary, In der neuesten Folge von Doc's Diary spreche ich mit Vivien Wysocki, Gründerin der Firma Saint Sass, über die Herausforderungen des Lebens als Selbstständige. Es geht um mentale Gesundheit, Stressbewältigung und den Druck, den das Unternehmertum mit sich bringt. Vivien teilt ihre persönlichen Erfahrungen, wie sie es schafft, Balance in ihrem Leben zu finden und welche Strategien sie nutzt, um in stressigen Phasen mental stark zu bleiben. Eine inspirierende Episode für alle, die selbst ein Business führen oder mit dem Gedanken spielen, den Schritt in die Selbstständigkeit zu wagen! Folge mir, DocAlina, auf Instagram und auf TikTok, um weitere Updates zu mir & meinem Podcast zu erhalten. Gast: @vivienwysocki / Werbung wegen Nennung: https://saintsass.com/ Doc's Diary ist ein Podcast von arc.studio. Learn more about your ad choices. Visit megaphone.fm/adchoices

Vivien Wysocki und Host Lili Vogelsang wollen herausfinden, wann es sich am besten lebt. Wann war's am besten? Und wie um Himmels Willen solle eine Maschine bei der Beantwortung der Frage helfen? Stimmt ab, ob die K.I. (Silke) oder Lili, ihr Gast und die Anrufer besser geantwortet haben! Hosted on Acast. See acast.com/privacy for more information.

In this special episode of the Exit Is Now podcast, EPI's Director of Marketing, Paige Wysocki, flips the script by interviewing Scott Snider. Together, they explore the importance of mentorship, innovation, and the professional growth of the team at the Exit Planning Institute (EPI). Scott dives into how EPI's marketing evolution has shaped the organization's brand and its impact on business attractiveness and readiness across the 4 C's. The conversation touches on decentralization for business owners, the value of documenting brand information, and how marketing plays a crucial role in value creation. They also discuss an exciting new project.Want to learn more? Go to: https://linktr.ee/theexitplanninginstituteConnect with Scott: https://www.linkedin.com/in/scott-snider-epi/============================================SUBSCRIBE TO THE PODCAST:Apple Podcasts: https://podcasts.apple.com/us/podcast/exit-is-now-plan-accordingly-with-scott-snider/id1663050204Spotify: https://open.spotify.com/show/0iXzdvQN1ApWPOk3rVytFR============================================CONNECT WITH SCOTT ON SOCIAL MEDIA   YouTube: https://www.youtube.com/channel/UC_Eh7TfhJHKRa5uc5R0uRgAFacebook: https://www.facebook.com/Exit-Planning-Institute-608403729259835Website: https://exit-planning-institute.org#ExitPlanningInstitute #ScottSnider #Podcast============================================About Scott:Scott Snider is the President of the Exit Planning Institute (EPI) and the Operating Partner of Snider Premier Growth, a small family investment company.  At EPI, Scott is responsible for the strategic direction of the organization along with overseeing the company's operations and chapter development. Since joining EPI, Scott has expanded the organization regionally, nationally, and globally, providing a transformational educational experience to advisors from all specialties across the globe.Scott Snider is a nationally recognized industry leader, growth specialist, and lifetime entrepreneur.  Two of Snider's biggest talents: market penetration and rapid growth strategies. As the operational and strategic leader of EPI, Snider thrives on helping advisors learn how to educate clients, achieve market distinction, and deliver real results.

Jason Fraley interviews The Fray drummer Ben Wysocki as the band releases its first new album in 10 years with “The Fray is Back" on Sept. 27, kicking off a comeback tour on the same day at the Lincoln Theatre in Washington D.C. Wysocki breaks down the band's biggest hits like “Over My Head (Cable Car),” “How to Save a Life,” “You Found Me," "Never Say Never" and "Heartbeat." (Theme Music: Scott Buckley's "Clarion") Learn more about your ad choices. Visit megaphone.fm/adchoices

Jason Fraley interviews The Fray drummer Ben Wysocki as the band releases its first new album in 10 years with “The Fray is Back" on Sept. 27, kicking off a comeback tour on the same day at the Lincoln Theatre in Washington D.C. Wysocki breaks down the band's biggest hits like “Over My Head (Cable Car),” “How to Save a Life,” “You Found Me," "Never Say Never" and "Heartbeat." (Theme Music: Scott Buckley's "Clarion") Learn more about your ad choices. Visit podcastchoices.com/adchoices

https://www.intentioncraft.com/What if you could parent without regrets? Join us this week as we sit down with Jake Wysocki, an expert in Design Thinking and a seasoned workshop facilitator, who shares the secrets behind living a regret-free life as a parent. Jake's innovative Design Your Regret-Free Life Parenting Workshops offer a tactical approach to live with intention and crush the goals you have for your family. In this episode he opens up his treasure trove of wisdom just for you. Learn the practical strategies for intentional living that Jake has honed over years of personal experience and professional expertise.Jake and his wife, Noelle, took a daring leap by quitting their jobs to embark on a year-long global adventure—a decision that forever changed their lives and their approach to parenting. This episode captures the essence of their journey, filled with thrilling stories from the Swiss Alps to the bustling streets of Japan. Want to learn more about their adventure? Check out their blog.Jake explains the concept of "memory dividends," where the joy of anticipation and recollection often surpasses the experience itself, and how this mindset can enrich your family's life. Discover how even the smallest, intentional moments can create lasting, joyful memories for you and your children.From weekly planning meetings that bring structure and harmony to family life, to empowering kids through inclusive goal-setting, Jake's insights are both practical and profound. He shares how adopting these strategies can reduce decision fatigue, foster family cohesion, and enable you to seize meaningful moments. Whether you're contemplating a bold life change or simply looking to optimize your daily routines, this episode is packed with actionable advice. Tune in and start your journey towards a more intentional, regret-free family life today.Check out Intention Craft & Schedule a free Coaching Call with Jake today.  The Thriving Family Accelerator provides an easy, 3-step process to lower stress, parent as a united team, and enjoy a true friendship with your spouse & relationship with your kids. Sign up now for this live parent coaching with proven methods for positively engaging your family and redistributing the mental load.

Jeremiah Wilber - (Ret) Army Green Beret, Mountain Man, Founder of War Party Movement, Cofounder War Party Ranch, Getto Vaquero, and Your Mom's Favorite Cowboy. Mikah Wysocki - Cowboygirl, 2022 Ranch Rodeo "Top Hand" Champion, Expert Horseman, Cofounder War Party Ranch, Domestic Violence Survivor, Cancer SurvivorAt War Party Movement, the ethos is about having "less thunder in the mouth and more lightning in the hand" and are taking action in breaking cycles of abuse and fundamentally changing the way women are treated, across the country and particularly in Native communities, through our 501(c)3 non-profit, War Party Ranch.War Party Ranch provides opportunities for women + girls to create working and life skills that foster independence and self-reliance in all aspects of their lives. WAR Party is building a community for these women focused in horsemanship, agriculture, hunting, firearms skills, self-defense, and health + wellness. Through education, sponsorship, and direct intervention we are continuously working to further this goal. As a for-profit organization, War Party Movement raises funds through the sale of products and merchandise to donate back to War Party Ranch. Funds go directly towards expenses for running the ranch, feed and care for our horses, putting on skills training clinics, providing services for women in our program, and sponsorships of War Party Ranch cowgirls, athletes, and partners.The sale of War Party Movement/War Party Ranch merchandise additionally helps to raise awareness for the cause -YOU ARE THE MOVEMENT!Tune in as Mikah Wysocki & Jeremiah Wilber join Bobby Marshall in studio to discuss the human trafficking epidemic, Native American culture, horsemanship, ranching, human perdition, domestic violence, hunting, veteran life, conservation, Colorado, outdoor life, and much more. Please subscribe or like us on social media platforms for updates on shows, events, and episode drops. www.themountainsidepodcast.com www.warpartymovement.comwww.warpartyranch.orgSponsor Links:www.JockoFuel.comMountain Side listeners receive 10% off all Jocko Fuel products! Use Code TMS10 to save. www.ONNIT.comMountain Side listeners use Discount code TMS to receive 10% off ONNIT products! www.BulletProof.comMountain Side listeners Use Discounts code: MOUNTAINSIDE to receive 20% off all Bulletproof products! Other Affiliates Links

Charlie Eisenhood and Josh Mansfield discuss the European Disc Golf Festival and the European Swing as it wrapped up over the weekend. Check out the Rapid Reax for more on EDGF. Then they dig into their mailbag (upshot@ultiworld.com) for some great questions from the listeners.0:00 Disc Golf & the World Games9:00 EDGF Recap12:50 European Swing Stats23:10 Mailbag!33:30 Jomez, Bag Changes, Drones52:45 Wysocki's Legacy & Conrad's Eli Manning Analogy1:05:20 EDGF #Pursewatch & Picks Review

REDIFF -Annick Golebiowski, 34 ans, Sandrine Wysocki, 24 ans. Deux amies fidèles qui se disaient tout. N'ignoraient rien des petits secrets de l'une et de l'autre et aimaient se retrouver dans les rues de Lens. En cette année 1992, elles vont disparaître, à dix mois d'intervalle, presque au même endroit. Seul le corps de l'une d'elle sera retrouvé dans une rivière.

REDIFF -Annick Golebiowski, 34 ans, Sandrine Wysocki, 24 ans. Deux amies fidèles qui se disaient tout. N'ignoraient rien des petits secrets de l'une et de l'autre et aimaient se retrouver dans les rues de Lens. En cette année 1992, elles vont disparaître, à dix mois d'intervalle, presque au même endroit. Seul le corps de l'une d'elle sera retrouvé dans une rivière.

REDIFF -Annick Golebiowski, 34 ans, Sandrine Wysocki, 24 ans. Deux amies fidèles qui se disaient tout. N'ignoraient rien des petits secrets de l'une et de l'autre et aimaient se retrouver dans les rues de Lens. En cette année 1992, elles vont disparaître, à dix mois d'intervalle, presque au même endroit. Seul le corps de l'une d'elle sera retrouvé dans une rivière.

Międzynarodowy Trybunał Karny wydał nakazy aresztowania byłego ministra obrony Rosji Siergieja Szojgu i szefa sztabu generalnego Walerija Gierasimowa. Mówimy też o strzelaninie 23 czerwca w Dagestanie i wcześniejszym buncie pod flagami ISIS w więzieniu w obwodzie rostowskim. Gość: Wacław Radziwinowicz, Gazeta Wyborcza. Piotr Wysocki, artysta multimedialny i reżyser filmu “Obczyzna” o uchodźcach z Inguszetii w Polsce, opowiada o ich życiu w ojczyźnie oraz na obczyźnie. Mówimy także o fascynującym rytuale zikr. Na antenie Trójki można było usłyszeć utwory: SadSvit - Toj xto pisniu hraw Avtomat – Toska Dmitriy Emelianov, Jurij Szewczuk - Pochorony wojny Można je znaleźć na playlistach Radio Wschód w Spotify: https://cutt.ly/BRLGvhP i na YouTube https://tinyurl.com/3995skds Po prostu Wschód w portalach społecznościowych: Kanał WhatsApp: https://whatsapp.com/channel/0029VaD6Ae17IUYMJUyd4Z1z Facebook: https://www.facebook.com/poprostuwschod Instagram: https://www.instagram.com/po_prostu_wschod/ Twitter: https://twitter.com/PogorzelskiP⁠⁠⁠ Po prostu Wschód na stronach Polskiego Radia: https://podcasty.polskieradio.pl/podcast/367 https://trojka.polskieradio.pl/audycja/10612 Przygotowanie audycji jest całkowicie sfinansowane przez Polskie Radio, jeśli jednak chcą Państwo mnie i tak wesprzeć, można to zrobić tu: https://patronite.pl/PiotrPogorzelski buycoffee.to/ppw

"To, co robią m.in. władze MIIWŚ, wynika z jakiejś nienawiści do naszego dziedzictwa narodowego"

On today's episode I honour the life, career and legacy of original Staind drummer Jon Wysocki who passed away on May 18th, 2024 at just 56 years old. He spent the last few years focused on his new band Lydia's Castle and today I interview the band's singer and guitarist Tonya LeeAnne and Cody Denton where they remember Jon. https://lydiascastle.com/ If you prefer to watch the episode instead of listen to it, you can do so on Youtube at: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtu.be/lWo5cEPA3YQ You can watch my first 2 hour deep dive interview with Jon on episode #68 where we cover his entire life, career and discography at: https://youtu.be/EV5TM6UwzSM You can watch my 2nd interview with Jon on episode #100 where we spend 2 hours talking about his 5 fav albums at: https://youtu.be/M7CwUMgP6Ew Leaving a like, a comment, a review or subscribing would really help the podcast to gain momentum and be a source of positive content for as many people as possible! Thank you for your support!                                                                         You can find all my social media links to connect with me at: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/joelmartinmastery⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Your friend and ally,                                                                                                                                           Joel Martin                                                                                                                                     We've Got Time by LiQWYD | https://www.instagram.com/liqwyd Music promoted by https://www.free-stock-music.com Creative Commons Attribution 3.0 Unported License https://creativecommons.org/licenses/by/3.0/deed.en_US

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss promising combination therapies and other compelling advances in genitourinary cancers in advance of the 2024 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I'm the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of genitourinary cancers at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that will be featured at the 2024 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode. Jeanny, it's great to have you on the podcast. Dr. Jeanny Aragon-Ching: Thank you so much, Dr. Agarwal. It's a pleasure to be here. Dr. Neeraj Agarwal: So, Jeanny, let's start with some bladder cancer abstracts. Could you tell us about the Abstract 4509 titled, “Characterization of Complete Responders to Nivolumab plus Gemcitabine Cisplatin versus Gemcitabine Cisplatin Alone in Patients with Lymph Node Only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial.”  Dr. Jeanny Aragon-Ching: Of course, Neeraj, I would be delighted to. First, I would like to remind our listeners that the CheckMate 901 trial was a randomized, open-label, phase 3 study, in which this particular sub-study looked at cisplatin-eligible patients with previously untreated, unresectable, or metastatic urothelial carcinoma who were assigned to receive the combination of gemcitabine and cisplatin, followed by up to 2 years of nivolumab or placebo. Based on the data presented at ESMO 2023 and subsequently published in the New England Journal of Medicine, which shows significantly improved progression-free survival and overall survival in patients receiving the combination of gemcitabine, cisplatin, and nivolumab, this regimen was approved in March 2024 as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma.  In the abstract that will be featured at ASCO this year, Dr. Matt Galsky and colleagues present a post-hoc analysis that aims to characterize a subset of patients with complete response as well as those with lymph node-only metastatic disease. In patients receiving the experimental treatment, 21.7% achieved a complete response, while 11.8% of the patients in the control arm achieved a complete response.  Among these complete responders, around 52% had lymph- node-only disease in both arms. Furthermore, when characterizing the subgroup of patients with lymph-node-only disease, those receiving the combination of gemcitabine-cisplatin plus nivolumab had a 62% reduction in the risk of progression or death and a 42% reduction in the risk of death compared to those treated with gemcitabine-cisplatin alone.  The median overall survival in the experimental arm in this subgroup was around 46.3 months, while it was only 24.9 months in the control arm. The ORR in patients with lymph-node-only disease receiving gem-cis plus nivo was about 81.5% compared to 64.3% in those treated with gem-cis alone. Dr. Neeraj Agarwal: Thank you, Jeanny, for the excellent summary of this abstract. We can say that nivolumab plus gemcitabine-cisplatin induced durable disease control and clinically meaningful improvements in OS and PFS compared to gem-cis alone in patients with lymph- node-only metastasis, and deserves to be considered as one of the options for these patients.  In a similar first-line metastatic urothelial carcinoma setting, Abstract 4502, also reported data on a recently approved combination of enfortumab vedotin and pembrolizumab. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, as quick reminder to our audience, this regimen was tested in the EV-302 phase 3 trial, where patients with previously untreated, locally advanced or metastatic urothelial carcinoma were randomized to receive enfortumab vedotin, plus pembrolizumab or gemcitabine plus either cisplatin or carboplatin. These data were also first presented at ESMO 2023 and subsequently published in the New England Journal of Medicine. They showed that this immune based combination significantly improved both progression free survival and overall survival, which were the primary endpoints compared to chemotherapy. In this abstract, Dr. Shilpa Gupta from the Cleveland Clinic and colleagues present the results of patient reported outcomes based on quality-of-life questionnaires in this trial.  Time to pain progression and time to confirm deterioration were numerically longer in patients treated with EV plus pembro, and patients with moderate to severe pain at baseline receiving this combination had a meaningful improvement in the Brief Pain Inventory Short-Form worst pain from week 3 through 26. Dr. Neeraj Agarwal: Thank you, Jeanny. This means that patients treated with EV plus pembro did not only have improved survival compared with platinum-based chemotherapy, but also improvement in their quality-of-life and functioning, further supporting the value of this combination for patients with locally advanced or metastatic urothelial carcinoma. This is terrific news for all of our patients.   Before we wrap up the bladder cancer section, would you like to tell our listeners about Abstract 4565, which provides the data on the efficacy of trastuzumab deruxtecan in patients with bladder cancer? Dr. Jeanny Aragon-Ching: Yes, Neeraj; this is timely given the recent FDA approval, which we will talk about. The abstract is titled, “Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2 Expressing Solid Tumors: Results from the Bladder Cohort of the DESTINY-PanTumor02 Study.” And as a quick reminder, the DESTINY-PanTumor02 was a phase 2 open-label study where trastuzumab deruxtecan, an antibody-drug conjugate targeting HER2 expression on cancer cells, was evaluated in patients with HER2-expressing locally advanced or metastatic disease who previously received systemic treatment or who had no other treatment options. The expression of HER2 was evaluated on immunohistochemistry by local or central testing.   The primary endpoint was confirmed objective response rate by investigator assessment. Secondary endpoints included duration of response, progression free survival, disease control rate, and safety. The primary analysis, which was published in the Journal of Clinical Oncology, showed an ORR of 37.1% and responses across all cohorts and the median duration of response was 11.3 months. Based on these results, fam-trastuzumab deruxtecan-nxki was just granted accelerated FDA approval for unresectable or metastatic HER2-positive solid tumors in April 2024.  So, back to this abstract; Dr. Wysocki and colleagues report the results of the bladder cancer cohort. This study included 41 patients with urothelial cancer and at a median follow up of around 12.6 months, the objective response rate among these patients was 39%, the median PFS was 7 months, and the duration of response median was 8.7 months. The disease control rate at 12 weeks was around 71%. Regarding the safety profile, 41.5% of patients experienced grade ≥3 drug related adverse events and interstitial lung disease or pneumonitis did occur in about 4 patients. Although there was no statistical comparison between different groups, the ORR was numerically highest among the HER2 3+ group with 56.3%.  Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data support consideration of trastuzumab deruxtecan as a salvage therapy option for pre-treated patients with HER2 expressing urothelial cancers and show that we are extending our treatment options to include therapies with novel mechanisms of action. This is definitely exciting news for patients with bladder cancer. Dr. Jeanny Aragon-Ching: Yes, absolutely, Neeraj. Now, let's switch gears a bit to prostate cancer. Could you tell us about Abstract 5005 which is titled, “EMBARK Post Hoc Analysis of Impact of Treatment Suspension on Health Quality-of-Life?” Dr. Neeraj Agarwal: Of course, I'd be happy to. So, enzalutamide was recently granted FDA approval for the treatment of patients with non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high-risk of metastasis, based on the results of the EMBARK trial, which was a phase 3 study where patients with high-risk biochemical recurrence were randomized to receive either enzalutamide with leuprolide, enzalutamide monotherapy, or placebo plus leuprolide. The primary endpoint was metastasis-free survival with secondary endpoints including overall survival and safety.  Results showed that patients receiving enzalutamide alone or enzalutamide plus leuprolide had significantly improved metastasis-free survival compared to those treated with leuprolide alone while preserving health-related quality-of-life.   One important aspect in the design of the trial was that patients who achieved undetectable PSA at week 37 underwent treatment suspension. The treatment was resumed if PSA rose to more than 2 ng/ml for patients who underwent radical proctectomy or when PSA rose to more than 5 ng/ml for those who did not undergo surgery.  In this abstract, Dr. Stephen Freedland and colleagues present a post-hoc analysis of health-related quality-of-life outcomes after treatment suspension between weeks 37 and 205. They found that treatment was suspended in 90.9% of patients receiving enzalutamide plus leuprolide, 85.9% of those receiving enzalutamide monotherapy, and 67.8% of those receiving leuprolide monotherapy. Among those patients who stayed on treatment suspension, a trend toward numerical improvement in health-related quality-of-life after week 37 was seen in all 3 arms and this reached clinically meaningful threshold at week 205 in pain questionnaires, physical well-being, urinary and bowel symptoms. For hormonal treatment side effects, all arms reached clinically meaningful improvement at the subsequent assessments of week 49 to week 97. However, patients slowly deteriorated, with clinically meaningful deterioration at week 205 relative to week 37 in patients receiving the combination of enzalutamide and leuprolide and those treated with leuprolide.    Concerning sexual activity, a clinically meaningful improvement was reported only in patients receiving enzalutamide plus leuprolide, possibly because sexual function was better preserved prior to suspension in the enzalutamide monotherapy arm and thus there was less opportunity for “improvement” while on suspension.  Dr. Jeanny Aragon-Ching: Thank you, Neeraj, for this great summary. This analysis confirms that treatment suspension in good responders might lead to a clinically meaningful improvements in health-related quality-of-life.   Now, moving on to patients with metastatic castration-resistant prostate cancer, what can you tell us, about Abstract 5008 titled, “Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore”?  Dr. Neeraj Agarwal: Sure, Jeanny. The PSMAfore trial was a phase 3 study that compared the efficacy of 177Lu-PSMA-617 versus an ARPI switch in patients with mCRPC and prior progression on a first ARPI, and not previously exposed to docetaxel chemotherapy. The primary endpoint was rPFS and OS was an important secondary endpoint. The primary analysis presented at ESMO 2023 showed a significantly prolonged rPFS in patients receiving lutetium. In the abstract that will be featured at the 2024 ASCO Annual Meeting, Dr. Johann De Bono and colleagues present an exploratory analysis regarding the associations between baseline circulating tumor DNA and outcomes.  ctDNA fraction was evaluated in all samples as well as alterations in key prostate cancer drivers prevalent in more than 10% of participants.  The investigators sought to interrogate the association of ctDNA fraction or alterations with rPFS, PSA response, and RECIST response at data cutoff. They showed that median rPFS was significantly shorter in patients with a ctDNA fraction >1% compared to those with a fraction < 1% regardless of the treatment arm. Furthermore, ctDNA fraction >1% was also associated with worst RECIST response and PSA50 response. Regarding prostate cancer drivers, median rPFS was significantly shorter in patients with alterations in the AR, TP53 or PTEN in both treatment arms. There was no significant association between ctDNA alterations and PSA or objective responses. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So, these results show that the presence of a ctDNA fraction >1% or alterations in AR, P53 and PTEN were all associated with worse outcomes regardless of treatment with lutetium or change in the ARPI. These data are definitely important for counseling and prognostication of patients in the clinic and may guide the design of future clinical trials. Let's move on to kidney cancer. Neeraj, do you have any updates for us?  Dr. Neeraj Agarwal:  Sure. In Abstract 4512 titled, “A Multi-institution Analysis of Outcomes with First-Line Therapy for 99 Patients with Metastatic Chromophobe Renal Cell Carcinoma,” Dr. Sahil Doshi and colleagues present a retrospective, multi-institutional study comparing survival outcomes, including time-to-treatment failure and overall survival, between different first-line treatment options in patients with metastatic chromophobe renal cell carcinoma, where limited clinical trial data exists to guide systemic therapy. They categorized patients into 4 treatment groups: and immune checkpoint inhibitors + targeted therapy doublets (such as ICI VEGF TKI); pure immune checkpoint inhibitor monotherapy and doublets (such as ipilimumab plus nivolumab); targeted therapy doublets (such as lenvatinib plus everolimus), and targeted monotherapy (such as sunitinib).  They identified 99 patients, of whom 54 patients received targeted monotherapy, 17 received ICI VEGF-TKI, 14 received targeted doublet, and 14 patients received only ICI therapies. So the patients treated with any doublet containing a targeted agent had a 52% decrease in the risk of treatment failure and a 44% decrease in the risk of death compared to those treated with targeted monotherapy. The median time to treatment failure was 15 months with IO-targeted doublet, and the median overall survival was 56 months. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So, these results show that targeted doublet regimens resulted in a longer time to treatment failure and overall survival compared to any monotherapy in patients with chromophobe metastatic RCC and definitely provides valuable insights on treatment selection, albeit I would say there's still a small number of patients that were included in this retrospective analysis. Dr. Neeraj Agarwal: I completely agree this is a relatively small number of patients, but I decided to highlight the abstract given how rare the cancer is, and it is highly unlikely that we'll see large randomized clinical trials in patients with metastatic chromophobe renal cell carcinoma.  So, before we wrap up the podcast, what would you like to tell us about Abstract 5009 which is titled, “A Phase II Trial of Pembrolizumab Platinum Based Chemotherapy as First Line Systemic Therapy in Advanced Penile Cancer: HERCULES (LACOG 0218) Trial.” Dr. Jeanny Aragon-Ching: I'm glad you brought this up, Neeraj. As our listeners may know, advanced penile squamous cell carcinoma has a poor prognosis with limited treatment options. From this perspective, the results of the LACOG 0218 trial are very important. As you mentioned, this was a phase 2 single-arm study evaluating the addition of pembrolizumab to platinum-based chemotherapy as first-line treatment in patients with metastatic or locally advanced penile squamous cell carcinoma not amenable to curative therapy. Patients enrolled received chemotherapy, namely 5-Fluorouracil with cisplatin or carboplatin and pembrolizumab 200 mg IV every 3 weeks for 6 cycles, followed by pembrolizumab 200 mg IV every 3 weeks up to 34 cycles. The primary endpoint was confirmed overall response rate by investigator assessment.  In the 33 patients eligible for the efficacy analysis, the confirmed ORR by investigator assessment was 39.4% and included one complete response and 12 partial responses. The confirmed ORR was 75% in patients with high TMB and 55.6% in patients positive for HPV16, making TMB and HPV16 potential predictive biomarkers for efficacy in this study. Concerning the toxicity profile, any grade treatment-related adverse events were reported in around 92% of patients, and grade 3 or more treatment-related adverse events occurred in 51% of patients. 10.8% of patients discontinued treatment due to adverse events.  Dr. Neeraj Agarwal: Thank you, Jeanny. I would like to add that HERCULES is the first trial to demonstrate the efficacy of an immune checkpoint inhibitor in advanced penile squamous cell carcinoma with a manageable safety profile. Thus, the combination of ICI with platinum-based chemotherapy is a promising treatment for advanced penile squamous cell carcinoma and warrants further investigation.  Dr. Jeanny Aragon-Ching: I agree, Neeraj. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Jeanny, I really want to thank you for your participation and valuable insights. Your contributions are always appreciated, and I sincerely thank you for taking the time to join us today. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. It was a pleasure.  Dr. Neeraj Agarwal:  As we bring this podcast to an end, I would like to acknowledge the significant advances happening in the treatment of patients with genitourinary cancers. During our upcoming 2024 ASCO Annual Meeting, there will be an array of different studies featuring practice-changing data presented by researchers and physicians from around the globe. I urge our listeners to not only participate in this event to celebrate these achievements, but to also play a role in sharing these cutting-edge data with healthcare professionals worldwide. Through our collective efforts, we can surely optimize the benefits of patients on a global scale.   And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you very much.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:  Dr. Neeraj Agarwal  @neerajaiims  Dr. Jeanny Aragon-Ching    Follow ASCO on social media:   @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn       Disclosures:    Dr. Neeraj Agarwal:     Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences    Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas     Dr. Jeanny Aragon-Ching:  Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono  Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,   Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics. 

After 19 years of working with traditional litigious (court driven process) divorces, attorney Cindy Wysocki now focuses entirely on collaborative divorce and helping families create agreements that work for their unique situations. Listen in to hear the difference between these two types of divorce, including costs, timeframe, and ability to customize agreements. Full show notes at https://meggluckman.com/podcast/120

Jon Wysocki was a drum hero and friend to so many. Jon passed away on May 18, 2024 at age 53.In this episode of Nu Pod, we delve into the making of Staind's iconic album "Break the Cycle" with drummer Jon Wysocki. Jon takes us on a journey through the writing process, making videos, and touring with Limp Bizkit. Join us as we explore the stories behind each track on this transformative album. We explore the themes and emotions that influenced the album's lyrical content. Jon Wysocki provides behind-the-scenes stories from the studio sessions and the band's approach to recording the album.  We go through "Break the Cycle" and how it solidified Staind's place in the rock music scene. Jon provides insights into the writing process and personal connections to each song.

On today's episode of the Music Minute, I share with a heavy heart that my friend and original Staind drummer Jon Wysocki passed away last night. If you prefer to watch the episode instead of listen to it, you can do so on Youtube at: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youtu.be/yTBhjuQVX9s You can watch my first 2 hour deep dive interview with Jon on episode #68 where we cover his entire life, career and discography at: https://youtu.be/EV5TM6UwzSM You can watch my 2nd interview with Jon on episode #100 where we spend 2 hours talking about his 5 fav albums at: https://youtu.be/M7CwUMgP6Ew Leaving a like, a comment, a review or subscribing would really help the podcast to gain momentum and be a source of positive content for as many people as possible! Thank you for your support! You can find all my social media links to connect with me at: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/joelmartinmastery⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Your friend and ally, Joel Martin We've Got Time by LiQWYD | https://www.instagram.com/liqwyd Music promoted by https://www.free-stock-music.com Creative Commons Attribution 3.0 Unported License https://creativecommons.org/licenses/by/3.0/deed.en_US

Miles is a fighter, both in the courtroom and out. When he's not at his desk preparing a case, you will most likely find him at a boxing gym preparing for a bout. The same tenacity and determination that he brings to the ring, he brings to his client's cases. Licensed in May of 2021, Miles began his practice of law in the personal injury field, were he learned how to press hard for his clients. While he excelled in this area, he was missing out on what he really wanted to do, litigate. In an effort to get into the courtroom and use his skills to help those in need, he turned to family law. Miles first had the thought to become an attorney as a child but didn't make the decision until his junior year in college. He obtained his bachelor's degree in Biology from the University of North Texas, then proceeded to study law at the Washburn University School of Law. The transition from spending nights in a laboratory, to nights in a law library was shocking at first, but Miles quickly found his stride studying law. During the summer of his 2L year he participated in the Intensive Trial Advocacy Program (ITAP) and got his first taste of courtroom litigation. After getting in front of a judge and jury for the first time, Miles knew that was where he belonged. Linkedin: https://www.linkedin.com/in/milesdavidpeterson/ O'Neil Wysocki: https://www.oneilattorneys.com/ Learn more about EmotionTrac and our AI-driven Emotional Intelligence Platform: https://legal.emotiontrac.com/

4/21/24 - Dr. Jacobs Talks with Sports Journalist Danni Wysocki by Dr. Andrew Jacobs

We are proud to have this episode presented by Disc Golf 978 USE CODE "welove978" at checkout for 5% off your entire order! https://discgolf978.com #ad POP DROP LOCK segment presented by Hooligan Discs! Use code STANCE10 for 10% off your order! https://hooligandiscs.com/ #ad If you'd like to play along with us for POP DROP LOCK visit www.popdroplock.com and set up a free account and check out the rules and play! Prizes provided by Hooligan Discs following each DGPT Elite or PDGA Major unless otherwise specified. Rules for now: https://docs.google.com/document/d/1mQ8wL7OXGBUcDYY0fJiXu28BYNTWCppbBR3x7lntxyU/edit?usp=sharing Gannon Buhr interview following his win at Prodigy Presents WACO, a Disc Golf Pro Tour PLUS event. Subscribe for more videos! Podcast: https://soundcloud.com/user-133590777 iTunes Spotify Google Follow Us: https://www.instagram.com/thestaggeredstance http://facebook.com/thenickandmattshow https://mobile.twitter.com/thenickandmatt1 Music LIcense: LY0XEIIZ6CWSMDGO XRVZVZ7BAOBWP7DX 1YAVSUTMQNQBG9PA KTNCHLXZHCSSWHNT

Today we're diving into a topic at the forefront of global innovation—sustainability in business. In this episode, we're honored to have two distinguished guests. Joining us is Cisco's Chief Sustainability Officer, Mary de Wysocki, whose vision and leadership are driving Cisco and its partners and customers towards a greener future. Interviewing Mary is the Founder and CEO of CyberSN, Deidre Diamond. Together, they'll share personal journeys, industry insights, and actionable strategies for embedding sustainability into the core of your business. So, buckle up as we explore the synergy between success and sustainability, right here, on From the Field.

Special guest...Mayor Jim Wysocki.Follow us on Facebook, Twitter and Instagram: @mahwahpodcastThis episode sponsored by CapitalOne Venture Card.

The doctor becomes the patient in this episode of the Gut Doctor podcast when Dr. Parikh's partner, Dr. John Wysocki- a fellow gastroenterologist- comes to the endoscopy center for his first screening colonoscopy. 

Annick Golebiowski, 34 ans, Sandrine Wysocki, 24 ans. Deux amies fidèles qui se disaient tout. N'ignoraient rien des petits secrets de l'une et de l'autre et aimaient se retrouver dans les rues de Lens. En cette année 1992, elles vont disparaître, à dix mois d'intervalle, presque au même endroit. Seul le corps de l'une d'elle sera retrouvé dans une rivière.

In this episode of the EY Sustainability Matters Podcast, host Bruno Sarda discusses with Mary de Wysocki, Chief Sustainability Officer at Cisco, how companies can leverage technology for a more sustainable future. The intersection between business, technology and sustainability is accelerating, with companies increasingly digitizing their operations. This can significantly reduce waste, energy and materials required to deliver products and services. However, de Wysocki warns that if digital transformation is not done in a sustainable manner, it could have a damaging effect on our planet due to the large energy needs of cloud service providers and data farms. Companies need to integrate sustainability into their digital transformation strategies and harness the value of data to drive these initiatives. De Wysocki also emphasizes the importance of deploying emerging technologies like Artificial intelligence (AI) and automation responsibly, considering the social dimensions such as ethics, privacy information, security, digital equity and human rights. Cisco is already embedding sustainability into its operations and moving towards a regenerative, green future. They have set three priorities in its environmental strategy - accelerating the transition to clean energy, evolving the business from linear to circular, and investing in resilient ecosystems. Cisco is also working on developing a data strategy to create consistent sustainability data across the enterprise, with rigorous reviews to ensure reliability and trust. De Wysocki concludes by highlighting the importance of partnerships and collaboration for achieving sustainability goals and emphasizes the need for inclusivity and a healthy planet for future generations. Key takeaways include: Digital technologies, like AI and automation, have the potential to transform the environmental impact of companies, reducing waste and lowering energy use. There are environmental impact risks posed by intensive energy users like the Information and Communications Technology sector and cloud service providers if not powered by clean energy. Sustainability needs to be integral to business strategy, with an emphasis on a “regenerative future”. Challenges include managing greenhouse gas emissions, addressing digital equity issues and appreciating the role of nature-based solutions in mitigating climate change. Companies should increase their commitment to transparency and accountability, and look to create partnerships in their value chain. © 2024 Ernst & Young LLP

Wiele lat temu studiowałem socjologię na Uniwersytecie Warszawskim. Filozofię mieliśmy na pierwszym roku w formie wykładów i ćwiczeń. A koledzy z tego wydziału który nazywał się Wydziałem Filozofii i Socjologii wydawali mi się wątłymi dziwakami, przy których nie można było zapalić papierosa z obawy, że wybuchnie powietrze. Nie przepadałem za tym przedmiotem. Lubiłem twardo stąpać do Ziemi. Od tamtego czasu minęły całe dekady, a jedną z najbardziej pasjonujących nauk w moim życiu stała się właśnie filozofia.W dzisiejszym odcinku wystąpił absolwent filozofii Andrzej Wysocki, który jest założycielem i dyrektorem szkoły wolnościowej Kastalia. Jak się okazuje, jest też absolwentem filozofii. Dlatego postanowiłem zaprosić go do podzielenia się osobistymi refleksjami i technikami i opowiedział słuchaczom, jak korzysta z filozofii w codziennym życiu i pracy.Postara się nim odpowiedzieć na pytania:Czym jest filozofia?Jak może pomoc nam radzić sobie z trudnościami i wyzwaniami życiowymi?Dlaczego wybrał studia filozoficzne?Jak się jej uczyć, by stała się światłem przewodnim na ścieżce osobistego rozwoju?Jakie są jego ulubione koncepcje filozoficzne związane z radzeniem sobie ze stresem i presją?Jakie są największe mity lub nieporozumienia dotyczące filozofii?Jakie książki filozoficzne poleca osobom, które chcą rozwijać się osobiście, korzystając z filozofii. i wiele innych

In this episode, educator Sarah Wysocki joins for an inspiring chat about leveraging generative AI like ChatGPT to customize learning for students from diverse backgrounds. You'll hear about innovative ways to use ChatGPT to generate ideas, help create accessible lessons, and tailor resources for a personalized learning experience. Show notes: https://classtechtips.com/2024/01/02/customized-learning-248/  Sponsored by my new free webinar: https://classtechtips.com/2024/  Follow Sarah on social: https://www.linkedin.com/in/sarah-wysocki-24043713a/  Follow Monica on Instagram: https://www.instagram.com/classtechtips/  Take your pick of free EdTech resources: https://classtechtips.com/free-stuff-favorites/   

Wir sprechen über Stumpfhosen mit Statement, Politik, Datenschutz und Aktien. Vivien Wysocki kommt aus Niedersachsen und wohnt in Berlin. Sie interessiert sich leidenschaftlich für Politik, modelt und ist Gründerin von ‚saint sass‘. Seid Ihr neugierig? Dann hört rein! **Mehr über Vivien Wysocki** * [LinkedIn](https://www.linkedin.com/in/vivienwysocki/) * [Instagram](https://www.instagram.com/vivienwysocki/) * [Twitter](https://twitter.com/vivienwysocki) * [saint sass](https://saintsass.com/) **Happy Immo** * [Website](https://happyimmoclub.com/) * [Podcasts](https://happyimmoclub.com/podcast) * [Instagram](https://www.instagram.com/happy_immo_club/) * [LinkedIn](https://www.linkedin.com/company/happyimmoclub) * [Club](https://www.linkedin.com/groups/9074824) - [Seminar](https://happyimmoclub.com/seminar/kurs)

In this episode of the Psych and Business Podcast, Dr. Ernest Wayde welcomes Dr. Leonard Wysocki, a psychological consultant specializing in emotional intelligence and leadership. Dr. Wysocki shares his intriguing career journey, transitioning from a 20-year career in business human resource management to coaching leaders in avoiding common pitfalls.Dr. Wysocki highlights the prevalent issue of smart individuals ascending the corporate ladder without essential emotional intelligence, leading to severe mistakes and job loss. His experiences in various industries, including aerospace, advertising, banking, and steel, revealed a consistent pattern of leaders lacking empathy and compassion.The conversation delves into the significance of emotional intelligence in leadership, with Dr. Wysocki emphasizing the importance of understanding individual motivations. He reflects on his own experiences working with a mentor who exemplified servant leadership, emphasizing the value of developing individuals. As a coach, Dr. Wysocki employs a coaching approach focused on becoming a trusted leadership advisor. He discusses a case where he helped a micromanaging vice president transform into a more effective leader through cognitive behavioral coaching, drawing parallels with cognitive behavioral therapy.The episode explores the challenges faced by executives in maintaining work-life balance, especially with the changing dynamics observed in the younger generation, and the importance of leaders understanding and motivating their team members.Dr. Wysocki shares insights into his coaching methodology, incorporating psychometric assessments to provide executives with a clear understanding of their emotional intelligence. He underlines the effectiveness of these assessments in initiating behavioral change and creating a starting point for coaching objectives.The conversation concludes with Dr. Wysocki offering a piece of advice to business leaders—“do unto others as you would have them do unto you.” He emphasizes the role of coaching in helping leaders navigate and understand the behavioral aspects crucial for successful leadership. You can visit his business website at: https://www.leonardwysockiphd.com/

“A key thing that I've learned along the way is that as leaders, we're always in the spotlight. And you need to always lead by example.”In this episode, I talk to Anthony Wysocki. Anthony has over 25 years of service with the US federal government. He currently serves as a director in the Office of the Inspector General in the US Department of Transportation.I invited him on the show today because he has a unique leadership challenge, and I think it's an intriguing one. Providing an internal oversight audit role, yet maintaining a service and relationship orientation. How do you do that as a leader? I talk to Tony about this challenge in this episode, as well as the personal challenge of neurodiversity awareness in organizations. This is a conversation you won't want to miss.In this episode:Anthony's journey and his role with the Office of Inspector General in the US Department of TransportationWhat Anthony learned about leadership along his journeyLeading by exampleThe importance of building relationships based on trustLeading as a neurodiverse individual And more!Power Presence Academy: Practical Wisdom for Leaders is the go-to podcast for anyone who leads. Your host is Janet Ioli, leadership and human development expert, sought-after coach and advisor to global executives, and former executive with experience in four Fortune 100 companies. She helps leaders ground themselves with confidence, connection, and purpose and learn to lead with Less Ego, More Soul.Resource Links:Anthony Wysocki is an energetic, strategic leader skilled in developing and inspiring self-managed teams that engage stakeholders and provide innovative and pragmatic solutions to organizational challenges. He has demonstrated an ability to establish an organizational vision that achieves multi-faceted goals and objectives. He consistently organizes and leads managers of diverse high-performance teams. He has effectively managed the performance of over 100 managers and professionals and contributed to their growth and advancement. Anthony is passionate about increased workplace diversity and inclusion through recruitment, hiring, and professional development opportunities that achieve mission results. Connect with today's guest on LinkedIn: Anthony WysockiConnect with Janet Ioli:Website: janetioli.comLinkedin: Janet IoliInstagram: @janetioliJanet is the founder of Power Presence Academy. She helps leaders ground themselves with confidence, connection, and purpose and lead with Less Ego, More Soul.If you want to become more grounded, confident, and aligned with your deeper values in just 21 days. Check out Janet Ioli's book Less Ego, More Soul: A Modern Reinvention Guide for Women.If you enjoyed this episode, please leave a review on Apple Podcasts. Select “Listen in Apple Podcasts,” then choose the “Ratings & Reviews” tab to share what you think.

In this episode of Nu Pod, we delve into the making of Staind's iconic album "Break the Cycle" with drummer Jon Wysocki. Jon takes us on a journey through the writing process, making videos, and touring with Limp Bizkit. Join us as we explore the stories behind each track on this transformative album. We explore the themes and emotions that influenced the album's lyrical content. Jon Wysocki provides behind-the-scenes stories from the studio sessions and the band's approach to recording the album.  We go through "Break the Cycle" and how it solidified Staind's place in the rock music scene. Jon provides insights into the writing process and personal connections to each song.  We end the epsiode with talk about what Jon is up to these days and speak on his current band, Lydia's Castle.

Nie mam syna. Nie zasadziłem drzewa i nie zbudowałem domu. Mam za to wspaniałego psa, który chyba mnie kocha. Ja go kocham najbardziej na świecie i mogę powiedzieć, że teraz jestem najszczęśliwszy w całym swoim dotychczasowym życiu.Mam pasję, której nie zamienię na żadną inną.Jest to jedyna rzecz, którą się nie znudziłem i nie zmieniłem po roku lub dwóch, jak inne opisane w mojej książce zajęcia. Realizuję ją dość długo, bo już 7 lat. Mam na myśli oczywiście podcasting.No i w końcu napisałem książkę. Ale nie zrobiłbym tego bez pomocy kilku osób, a najbardziej jednej, która zgodziła się na chwilę wystąpić w tym odcinku. Mam na myśli wieloletniego słuchacza Lepiej Teraz, Andrzeja Wysockiego, który kilka lat temu odpowiedział na moje zapytanie, wystosowane do słuchaczy Lepiej Teraz.W tym odcinku;Skąd pojawił się pomysł na napisanie książki?Jak wyglądały moje początki pisarskie?O jaką pomoc poprosiłem moich słuchaczy?Dlaczego Andrzej Wysocki zaproponował swoją pomoc w pisaniu?Czym na codzień zajmuje sie Andrzej Wysocki?Jak pisanie wiąże się z filozofią i prowadzeniem demokratycznej szkoły KASTALIA?Na czym polegała jego praca?Skąd brałem informacje potrzebne, do stworzenia książki?Jak wyglądał nasz workflow przy pisaniu książki?Które rozdziały mojej książki najbardziej mu się spodobały?Dlaczego prawie zrezygnowałem z napisania książki?Jak wyglądały poszczególne etapy tworzenia książki? Od pomysłu do sprzedaży?Ile czasu zajęło mi nagranie audiobooka?i wiele innych O tym, jak stoicyzm pomaga zmienić życie na lepsze, opowiadam w bardzo osobistej autobiografii i poradniku, pt. „Podcaster” którą możecie już kupić na stronie www.lepiejteraz.pl w postaci książki papierowej, e-booka oraz audiobooka (który osobiście nagrałem!)

Annick Golebiowski, 34 ans, Sandrine Wysocki, 24 ans. Deux amies fidèles qui se disaient tout. N'ignoraient rien des petits secrets de l'une et de l'autre et aimaient se retrouver dans les rues de Lens. En cette année 1992, elles vont disparaître, à dix mois d'intervalle, presque au même endroit. Seul le corps de l'une d'elle sera retrouvé dans une rivière. Retrouvez tous les jours en podcast le décryptage d'un faits divers, d'un crime ou d'une énigme judiciaire par Jean-Alphonse Richard, entouré de spécialistes, et de témoins d'affaires criminelles. Ecoutez L'heure du Crime du 30 mai 2023 avec Jean-Alphonse Richard.

Annick Golebiowski, 34 ans, Sandrine Wysocki, 24 ans. Deux amies fidèles qui se disaient tout. N'ignoraient rien des petits secrets de l'une et de l'autre et aimaient se retrouver dans les rues de Lens. En cette année 1992, elles vont disparaître, à dix mois d'intervalle, presque au même endroit. Seul le corps de l'une d'elle sera retrouvé dans une rivière. Retrouvez tous les jours en podcast le décryptage d'un faits divers, d'un crime ou d'une énigme judiciaire par Jean-Alphonse Richard, entouré de spécialistes, et de témoins d'affaires criminelles. Ecoutez L'heure du Crime du 30 mai 2023 avec Jean-Alphonse Richard.

As April is Earth Month, who better to have as a guest than Mary de Wysocki, Cisco's very own Chief Sustainability Officer. Mary sits down with AB to chat about her role in leading Cisco's sustainability efforts and how we need to work together on a global level to create more sustainable and resilient communities.

As April is Earth Month,  who better to have as a guest than Mary de Wysocki, Cisco's very own Chief Sustainability Officer. Mary sits down with AB to chat about her role in leading Cisco's sustainability efforts and how we need to work together on a global level to create more sustainable and resilient communities.

16:28 - Jesse Jahner - Cass County Sheriff 21:31 - Mark Empting - Clay County Sheriff 39:37 - Jesse Grabow - Minnesota State Patrol Sergeant 51:06 - Bryan Niewind - North Dakota Highway Patrol Captain 55:07 - Chris Pilkerton - Former Manhattan ADA and former Trump White House Senior Advisor 1:16:01 - Wayne Root - Host of "Wayne Allyn Root: Raw and Unfiltered" on USA Audio Network and star of two new TV shows - "America's Top Ten Countdown with Wayne Allyn Root" on Real Americas Voice TV Network and his daily "The Wayne Allyn Root Show" on Lindell TV 1:43:14 - Dean Wysocki - Chief Meteorologist at Flag Family Media What's on your mind? We want to know! Email us at StudioFlagFamily [dot] com Subscribe on Spotify, Apple, & Google  

19:25 - Daniel Damico - Worship Arts Director at First Lutheran Church 1:09:57 - Dean Wysocki - Chief Meteorologist at Flag Family Media 1:17:27 - Raymond Arroyo - Author, The Unexpected Light of Thomas Alva Edison 1:44:47 - Mark Wagner - ND Estate Services What's on your mind? We want to know! Email us at StudioFlagFamily [dot] com Subscribe on Spotify, Apple, & Google

Followed her intuition that revealed extraordinary life lessons. Join Shannon and I as she retells the adventures she experienced as she followed her intuition - travel, stuck in Italy during the outbreak of covid, illness and self-discovery. Shannon trust in her intuition enabled her to follow a mystery name she could hear but didn't know! This led her on a journey of self-discovery, not an easy passage and one full of the unexpected!! (Amazon)Shannon's Book : https://geni.us/Abrushworldsunseen Lorraine's website: lorrainenilon.com.au Book a personal session with Lorraine https://calendly.com/lorrainenilon/60min Check out Gems of Wisdom from episode 27- Use them as journal prompts, contemplation points or conversation starters. https://www.facebook.com/LorraineNilon A special WORDS OF WISDOM form for reviews - https://form.jotform.com/Insight.../words-of-wisdom-reviews- Thought-Provoking videos and Flip the Book - https://youtube.com/@lorrainenilon Support the show- https://www.buymeacoffee.com/LorraineNilon Music by Joystock - https://www.joystock.org

*This episode is part of a series highlighting stories in Albemarle, North Carolina*In this episode of our podcast, we sit down with Mary Wysocki, a City of Albemarle native who found her calling in the world of custom apparel. After feeling unfulfilled in the corporate world, Mary began experimenting with wooden signs as a creative outlet. But it wasn't until she discovered heat transfer vinyl that her hobby truly took off. From there, she began advertising on social media, selling on Etsy, and eventually opening her first retail location in 2015. Join us as Mary shares her story of turning her passion into a thriving business and how she adds a personal touch to every piece she creates.https://makeitpersonalbymm.com/https://www.instagram.com/makeitpersonalbymm/https://www.facebook.com/makeitpersonalbymarymargarethttps://www.albemarlenc.gov/https://www.albemarledowntown.com/https://visitstanly.com/Host-Amelia OldVoices of Inspiration PodcastInstagramTikTokLinkedinYoutube

We are joined on today's USDF episode by Kristi Wysocki for more review of the new 2023 tests. Listen in...GUESTS AND LINKS DRESSAGE EPISODE 693:Co-Hosts: Reese Koffler-Stanfield and Philip ParkesGuest: Kristi WysockiDressage Book Club: Horse Brain, Human Brain - The Neuroscience of Horsemanship by Janet Jones, PhDHRN Merchandise!  Find a complete line of screen printed stuff....  and The embroidered merchandise at...Download the FREE Horse Radio Network app for iPhone and AndroidFollow Dressage Radio Show on  Facebook, and follow Horse Radio Network on TwitterCheck out this other great show in the HRN family: Healthy Critters RadioPlease visit our sponsors, who make all this possible Kentucky Performance Products, Ride IQSupport the show

"We were born not to sue but to command." - William Shakespeare Dr.Joe Wysocki of the Belmont Abbey College is here to discuss the making of monarchies, kings, statesmen and families through the lens of Shakespeare's Henriad.   Check out the Belmont Abbey Honors College- the newest of our endorsed institutions: https://belmontabbeycollege.edu/academics/honors-college/   Dr. Joseph Wysocki is Dean of the Honors College at Belmont Abbey College where he has also served as Assistant Academic Dean, and Chair and Associate Professor of the Politics Department since 2010. He is interested in all of the great books in the Honors College curriculum but has a particular focus on classical political philosophy and American political thought, especially the thought of Alexis de Tocqueville. Dr. Wysocki received his B.A. in Political Science and Economics from Belmont Abbey College and his M.A. and Ph.D in Political Science at Baylor University. He serves on the Council of Scholars for the American Academy for Liberal Education and CLT's Board of Academic Advisors. He lives in Gastonia, NC with his wife Jeanne and his six children.